CONSIDERATIONS | SUSPECTED SJS, TEN, OR DRESS | Confirmed SJS, TEN, OR DRESS |
---|---|---|
Dose modification with OPDIVO, OPDIVO + YERVOY, or OPDIVO Qvantig |
Withhold treatment | Permanently discontinue treatment |
Management | Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Administer 1 to 2 mg/kg/day prednisone or equivalent until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. |
|
Follow-up | Consider administration of other systemic immunosuppressants, including corticosteroid therapy, if clinically appropriate. |
Signs, symptoms, grading, and management
Immune-mediated dermatologic adverse reactions
Signs and symptoms of dermatologic adverse reactions may include new or worsening1,2
- Rash
- Itching
- Skin blistering or peeling
- Swollen lymph nodes
- Painful sores or ulcers in mouth, nose, throat, or genital area
- Fever or flu-like symptoms
Management considerations for immune-mediated dermatologic adverse reactions1,2
When OPDIVO is administered in combination with YERVOY, if OPDIVO is withheld or discontinued, YERVOY should also be withheld or discontinued.1
Dosing Information
Find the appropriate dosing information for your patients in any approved regimen.
OPDIVO Dosing Guide
A guide to dosing across all indications.
Patient Monitoring Checklist
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
References:
- OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- OPDIVO Qvantig [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.